Stockscreener 앱 받기
11.73
0.59%
-0.07
전일 마감가:
$11.80
열려 있는:
$11.72
하루 거래량:
287.77K
Relative Volume:
0.26
시가총액:
$999.68M
수익:
-
순이익/손실:
$-119.87M
주가수익비율:
-6.4807
EPS:
-1.81
순현금흐름:
$-109.90M
1주 성능:
+5.30%
1개월 성능:
+11.82%
6개월 성능:
+13.55%
1년 성능:
+8.81%
1일 변동 폭
$11.53
$11.91
1주일 범위
$10.88
$12.00
52주 변동 폭
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
11.73 | 950.19M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
Can ORIC Pharmaceuticals Inc. stock recover from recent declineBreakthrough profit margins - jammulinksnews.com
What drives ORIC Pharmaceuticals Inc. stock priceUnprecedented growth rates - PrintWeekIndia
ORIC Pharmaceuticals Inc. Stock Analysis and ForecastTriple-digit wealth increases - Autocar Professional
What analysts say about ORIC Pharmaceuticals Inc. stockFree Smart Trading Workshop - Autocar Professional
Arizona State Retirement System Invests $56,000 in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Is ORIC Pharmaceuticals Inc. a good long term investmentFree Trading Psychology Coaching - jammulinksnews.com
How high can ORIC Pharmaceuticals Inc. stock price go in 2025Massive Gain Ideas - Newser
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Why ORIC Pharmaceuticals Inc. stock attracts strong analyst attentionFree Capital Allocation Plans - Newser
What makes ORIC Pharmaceuticals Inc. stock price move sharplySmart High Yield Swing Trades - Newser
How ORIC Pharmaceuticals Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 4.9%Should You Sell? - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated by Analysts at LADENBURG THALM/SH SH - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Research Coverage Started at LADENBURG THALM/SH SH - Defense World
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Consensus Price Target from Analysts - MarketBeat
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.32%
1.57%
자본화:
|
볼륨(24시간):